immunoglobulin G4-kappa, anti-[Homo sapiens CD47 (CD47 molecule, integrin associated protein, IAP, MER6, OA3)] and anti-[Homo sapiens CD274 (programmed cell death 1 ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1, B7-H1, PDCD1LG1)], humanized monoclonal antibody, bispecific, bivalent
Lymphoma
Mabwell (Shanghai) Bioscience Co., Ltd.monoclonal_antibodyPhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 65/ 100
Competitive context
288 Active assets in the Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINBLASTINE Intensity Therapeutics, Inc. | Phase 4 | BBB |
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE The Lymphoma Academic Research Organisation | Phase 4 | BBB |
BLEOMYCIN Shandong Provincial Hospital | Phase 4 | BB |
VINCRISTINE SULFATE Inhye Ahn | Phase 3 | BB |
(+)-VINCRISTINE Beth Israel Deaconess Medical Center | Phase 4 | BB |
View all 50 →
Same molecule, other indications
immunoglobulin G4-kappa, anti-[Homo sapiens CD47 (CD47 molecule, integrin associated protein, IAP, MER6, OA3)] and anti-[Homo sapiens CD274 (programmed cell death 1 ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1, B7-H1, PDCD1LG1)], humanized monoclonal antibody, bispecific, bivalent is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →